company background image
ANIK logo

Anika Therapeutics NasdaqGS:ANIK Stock Report

Last Price

US$25.54

Market Cap

US$374.5m

7D

-0.2%

1Y

-10.5%

Updated

27 Mar, 2024

Data

Company Financials +

Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$374.5m

ANIK Stock Overview

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

ANIK fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Anika Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anika Therapeutics
Historical stock prices
Current Share PriceUS$25.54
52 Week HighUS$29.26
52 Week LowUS$16.54
Beta0.75
1 Month Change0.55%
3 Month Change12.81%
1 Year Change-10.51%
3 Year Change-37.39%
5 Year Change-15.71%
Change since IPO629.71%

Recent News & Updates

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Recent updates

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Aug 03
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Mar 11

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Jun 25
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Anika Therapeutics (ANIK) Presents At UBS Global Healthcare Virtual Conference - Slideshow

May 28

Anika Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Anika Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Shareholder Returns

ANIKUS BiotechsUS Market
7D-0.2%0.9%0.4%
1Y-10.5%10.3%28.8%

Return vs Industry: ANIK underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ANIK underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ANIK's price volatile compared to industry and market?
ANIK volatility
ANIK Average Weekly Movement4.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ANIK has not had significant price volatility in the past 3 months.

Volatility Over Time: ANIK's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983357Cheryl Blanchardhttps://www.anika.com

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.

Anika Therapeutics, Inc. Fundamentals Summary

How do Anika Therapeutics's earnings and revenue compare to its market cap?
ANIK fundamental statistics
Market capUS$374.47m
Earnings (TTM)-US$82.67m
Revenue (TTM)US$166.66m

2.2x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANIK income statement (TTM)
RevenueUS$166.66m
Cost of RevenueUS$62.83m
Gross ProfitUS$103.84m
Other ExpensesUS$186.50m
Earnings-US$82.67m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-5.64
Gross Margin62.30%
Net Profit Margin-49.60%
Debt/Equity Ratio0%

How did ANIK perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.